Home › Funds › DRIEHAUS CAPITAL MANAGEMENT LLC › SYRE

DRIEHAUS CAPITAL MANAGEMENT LLC position in SYRE

SPYRE THERAPEUTICS INC · Health Care

DRIEHAUS CAPITAL MANAGEMENT LLC reported holding 2,799,166 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$248.5M, representing 1.44% of its reported portfolio and ranking #6 among its reported holdings. DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed SYRE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.80M sh
Reported value held$248.51M
Portfolio Weight1.44%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How DRIEHAUS CAPITAL MANAGEMENT LLC's SYRE position evolved

DRIEHAUS CAPITAL MANAGEMENT LLC first disclosed a stake in SYRE in Q3 2023 at 800,853 shares (US$9.8M). The position peaked in Q2 2026 at 2,799,166 shares, worth US$248.5M. Across 12 filings, DRIEHAUS CAPITAL MANAGEMENT LLC increased the stake 2 time(s), trimmed it 6 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 2,799,166 shares valued at US$248.5M. Notable position changes include a 308% increase in Q4 2024 (shares fell 31% over the following quarter), a 40% increase in Q4 2025 (shares rose 54% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 800.85K $9.81M New
Q4 2023 771.90K $16.61M Reduce
Q1 2024 687.08K $26.06M Reduce
Q2 2024 687.08K $16.15M Hold
Q3 2024 687.08K $20.21M Hold
Q4 2024 2.80M $65.27M Add
Q1 2025 2.72M $43.84M Reduce
Q2 2025 2.09M $31.22M Reduce
Q3 2025 2.06M $34.53M Reduce
Q4 2025 2.88M $94.43M Add
Q1 2026 2.79M $140.77M Reduce
Q2 2026 2.80M $248.51M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has DRIEHAUS CAPITAL MANAGEMENT LLC held SYRE?

DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed SYRE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is DRIEHAUS CAPITAL MANAGEMENT LLC's current position in SYRE?

As of Q2 2026, DRIEHAUS CAPITAL MANAGEMENT LLC holds 2.80M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $248.51M, representing 1.44% of its reported portfolio and ranking #6.

Has DRIEHAUS CAPITAL MANAGEMENT LLC been buying or selling SYRE?

In the latest 13F filing (Q2 2026), DRIEHAUS CAPITAL MANAGEMENT LLC held unchanged its position in SYRE. The position peaked in Q2 2026 at 2.80M shares.

Which other funds hold SYRE?

Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 70 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.